Arcus Biosciences, Inc.

Arcus Biosciences is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and, to a lesser extent, inflammatory and autoimmune diseases. The company does not sell commercial products today; instead, it advances a pipeline of investigational antibodies and combination regimens through partnerships with larger pharmaceutical companies. Its business model is built around R&D execution, collaboration revenue, and milestone/option economics rather than product sales. Arcus is headquartered in Hayward, California and operates as a single reportable segment. The company relies heavily on third-party manufacturers and collaborators to fund, de-risk, and help advance its programs.

−152,2 %

−142,9 %

−4,3 %

4.36

4.36

— Arcus Biosciences, Inc.
%
Oncology immunotherapy pipeline70% Investigational cancer therapies including anti-TIGIT, adenosine-pathway and HIF-2α programs developed for solid tumors.
Collaborative R&D services25% Development work performed under collaboration agreements where revenue is recognized over time as obligations are satisfied.
License and option arrangements5% Upfront, milestone and option-related consideration from partners such as Gilead, Taiho and AstraZeneca.

Arcus does not have traditional end customers for product sales; its revenue comes from strategic pharmaceutical...

  • Strategic pharmaceutical collaboratorsprimary

    Large pharma partners that pay upfronts, milestones, option fees and fund joint development to access Arcus’s pipeline and share risk.

  • Clinical development partnersprimary

    Companies participating in combination trials and joint studies to evaluate Arcus assets in specific tumor settings.

  • Future oncology treatment buyersemerging

    Hospitals, oncologists and reimbursing payers that would buy approved therapies if Arcus successfully commercializes a product.

Arcus is headquartered in Hayward, California and is organized as a U.S.-based biotechnology company...

  • •Headquartered in Hayward, California, United States
  • •No disclosed country-level revenue mix in the provided excerpts
  • •Clinical trials and supply chains extend into multiple countries
  • •Third-party manufacturing and CRO activity create cross-border execution risk
  • •Commercial geography is not yet established because no product sales exist

Arcus’s strategy is to advance a differentiated oncology pipeline through late-stage clinical development while using...

01
Progress key oncology programs through clinical milestonesshort-term

Clinical success is the main driver of valuation and future partnering/commercial potential.

02
Deepen and monetize strategic collaborationsmedium-term

Partnerships provide non-dilutive funding, external validation and shared development capacity.

03
Maintain liquidity and development flexibilityshort-term

The company must fund substantial R&D before any product revenue is available.

Arcus faces the core biotechnology risk that its investigational products may fail in clinical development, receive...

critical

Failure to obtain or delay in obtaining regulatory approval

The company’s value depends on investigational products reaching approval; delays materially harm the business.

Scope
All pipeline assets
Materiality
high
high

Clinical development and trial enrollment setbacks

Trial outcomes, enrollment speed and comparator drug availability directly affect development timelines and costs.

Scope
Quemliclustat, domvanalimab, casdatifan and other programs
Materiality
high
high

Supply chain and third-party manufacturing disruption

Arcus relies on single-source or external manufacturers for API, drug product and trial materials.

Scope
Investigational products and clinical supply
Materiality
high
high

Competitive pressure in oncology immunotherapy

Larger peers may launch better or faster therapies, reducing Arcus’s commercial opportunity.

Scope
Anti-TIGIT and adenosine-pathway programs
Materiality
high
high

Dependence on collaboration revenue and partner actions

Revenue recognition and cash inflows depend on partner funding, milestones and continued development.

Scope
Gilead, Taiho and AstraZeneca agreements
Materiality
high
Revenue recognition for collaboration agreements
Large quarter-to-quarter swings and potential cumulative catch-up adjustments
Deferred revenue related to Gilead upfront payments
Future revenue timing and magnitude
Standalone selling price estimates
Revenue allocation across periods
Impairment of long-lived assets
Operating expense volatility

PRECISION BIOSCIENCES INC

DTIL · Biological Products, (No Diagnostic Substances)

Arcturus Therapeutics Holdings Inc.

ARCT · Pharmaceutical Preparations

Arcellx, Inc.

Biological Products, (No Diagnostic Substances)

Arcutis Biotherapeutics, Inc.

ARQT · Pharmaceutical Preparations

TuHURA Biosciences, Inc./NV

HURA · Pharmaceutical Preparations

Oric Pharmaceuticals, Inc.

ORIC · Pharmaceutical Preparations

: 11/08/2026